ARS Pharmaceuticals, Inc. — Director's Dealing 2021

Dec 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2021-12-13

Reporting Person: ROOT JONATHAN D (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-13	Common Stock	J	2069167	—	Disposed	0	Indirect
2021-12-13	Common Stock	J	105012	—	Disposed	0	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	95238	Direct

Footnotes

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners XII, L.P. ("USVP XII") and by U.S. Venture Partners XII-A, L.P. ("USVP XII-A"), without additional consideration, to its partners.

F2: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.